Alumis (ALMS) Stock Price, News & Analysis

Company Overview

Alumis (NASDAQ: ALMS) is a specialty aluminum manufacturer and distributor focusing on the production and value-added processing of aluminum sheet, coil, plate, foil and extruded products. The company offers end-to-end solutions including slitting, shearing, annealing, edging and surface finishing to meet the precise specifications of its industrial customers. Alumis leverages proprietary alloy formulations and precision processing capabilities to deliver materials for demanding applications in automotive, aerospace, packaging, electronics, construction and consumer goods markets.

Throughout its operations, Alumis emphasizes quality assurance and technical support, providing metallurgical expertise and application engineering to optimize product performance. Its product portfolio encompasses standard and high-strength aluminum alloys, custom-tuned temper profiles and specialty surface treatments designed to enhance corrosion resistance and formability. The company’s value-added services include just-in-time inventory management, supply-chain logistics and collaborative research projects in partnership with OEMs and Tier 1 suppliers.

Founded in 1968 and headquartered in Cleveland, Ohio, Alumis has grown through a combination of organic expansion and strategic acquisitions. Today, the company operates multiple manufacturing and processing facilities across North America and Europe, serving a global customer base. Its geographic footprint enables close collaboration with regional customers while maintaining centralized technical and quality oversight.

Under the leadership of CEO John P. Farrelly and CFO Patricia Walsh, Alumis continues to invest in process automation, sustainability initiatives and advanced metallurgy. The executive team draws on decades of industry experience to drive operational efficiencies and innovation, positioning the company to capitalize on emerging trends such as lightweighting in transportation and enhanced recyclability in packaging.

Key Stats

• Today's Range: $3.20 to $3.41
• 50-Day Range: $2.80 to $5.95
• 52-Week Range: $2.76 to $13.50
• Volume: 541,917 shs
• Average Volume: 428,056 shs
• Market Capitalization: $180.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.86
• Consensus Rating: Buy

Alumis Stock Analysis - MarketRank™

Alumis scored higher than 58% of companies evaluated by MarketBeat, and ranked 421st out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Alumis has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Alumis has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Alumis are expected to grow in the coming year, from ($8.51) to ($4.19) per share.

Price to Book Value per Share Ratio

Alumis has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ALMS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alumis does not currently pay a dividend.

Dividend Growth

Alumis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ALMS.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

16 people have searched for ALMS on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Alumis to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Alumis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,678,864.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

40.70% of the stock of Alumis is held by insiders. A high percentage of insider ownership can be a sign of company health.

ALMS Stock Analysis - Frequently Asked Questions

How have ALMS shares performed this year?

Alumis' stock was trading at $7.86 at the start of the year. Since then, ALMS stock has decreased by 57.9% and is now trading at $3.31.

How were Alumis' earnings last quarter?

Alumis Inc. (NASDAQ:ALMS) posted its quarterly earnings results on Wednesday, May, 14th. The company reported ($1.82) earnings per share for the quarter, missing analysts' consensus estimates of ($1.47) by $0.35.

When did Alumis IPO?

Alumis (ALMS) raised $210 million in an initial public offering on Friday, June 28th 2024. The company issued 13,125,000 shares at $16.00 per share.

Who are Alumis' major shareholders?

Alumis' top institutional investors include Kera Capital Partners Inc. (0.02%).
View institutional ownership trends.

How do I buy shares of Alumis?

Shares of ALMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Alumis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alumis investors own include Comstock (LODE), Ashford Hospitality Trust (AHT), Artificial Intelligence Technology Solutions (AITX), Allakos (ALLK), BioXcel Therapeutics (BTAI), Clearside Biomedical (CLSD) and Delcath Systems (DCTH).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALMS
• Previous Symbol: NASDAQ:ALMS
• CIK: 1847367
• Web: N/A
• Phone: (650) 231-6625
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $22.86
• High Stock Price Target: $36.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +590.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.22
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$294.23 million
• Net Margins: N/A
• Pretax Margin: -1,974.51%
• Return on Equity: -406.27%
• Return on Assets: -107.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.73
• Quick Ratio: 3.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.51 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 54,410,000
• Free Float: 32,263,000
• Market Cap: $180.10 million
• Optionable: N/A
• Beta: N/A